Prognostic factors of intraperitoneal chemotherapy for peritoneal carcinomatosis of gastric cancer: A retrospective study from a single center

  • Authors:
    • Hai-Tao Men
    • Hong-Feng Gou
    • Ji-Yan Liu
    • Qiu Li
    • De-Yun Luo
    • Feng Bi
    • Meng Qiu
  • View Affiliations

  • Published online on: April 1, 2016     https://doi.org/10.3892/ol.2016.4403
  • Pages: 3501-3507
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Peritoneal carcinomatosis (PC) of gastric origin is currently recognized as a terminal disease with a poor prognosis. Advancements in novel therapeutic approaches, including intraperitoneal chemotherapy (IPC), have recently been made and it is believed that this may have contributed to the improved survival observed in patients with PC. The present study aimed to investigate overall survival (OS) and the associated prognostic factors in patients with PC of gastric origin who underwent IPC. A total of 57 patients were studied, with a median age of 51 years. The median follow‑up time was 12.4 months. PC was diagnosed in all patients with gastric cancer. The median survival time of all patients was 10.1 months, whilst the OS rate at 1, 2 and 3 years was observed to be 46, 19 and 12%, respectively. Symptomatic ascites and a signet ring cell (SRC) histopathological type were demonstrated to signify a poor prognosis. Complete resection of all gross disease (CCR‑0) and an increased number of cycles of systemic chemotherapy were independent factors that were observed to correlate with increased OS. The most common morbidities of grade 3/4 adverse effects were bone marrow suppression, nausea or vomiting, and diarrhea. In conclusion, IPC is an important treatment option for patients with PC that has originated from gastric cancer. Symptomatic ascites and SRC adenocarcinoma serve as negative clinicopathological prognostic factors, whilst CCR-0 and increased systemic chemotherapy cycles (≥4 cycles) may prove to be an important therapeutic option for PC patients.
View Figures
View References

Related Articles

Journal Cover

May-2016
Volume 11 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Men H, Gou H, Liu J, Li Q, Luo D, Bi F and Qiu M: Prognostic factors of intraperitoneal chemotherapy for peritoneal carcinomatosis of gastric cancer: A retrospective study from a single center. Oncol Lett 11: 3501-3507, 2016
APA
Men, H., Gou, H., Liu, J., Li, Q., Luo, D., Bi, F., & Qiu, M. (2016). Prognostic factors of intraperitoneal chemotherapy for peritoneal carcinomatosis of gastric cancer: A retrospective study from a single center. Oncology Letters, 11, 3501-3507. https://doi.org/10.3892/ol.2016.4403
MLA
Men, H., Gou, H., Liu, J., Li, Q., Luo, D., Bi, F., Qiu, M."Prognostic factors of intraperitoneal chemotherapy for peritoneal carcinomatosis of gastric cancer: A retrospective study from a single center". Oncology Letters 11.5 (2016): 3501-3507.
Chicago
Men, H., Gou, H., Liu, J., Li, Q., Luo, D., Bi, F., Qiu, M."Prognostic factors of intraperitoneal chemotherapy for peritoneal carcinomatosis of gastric cancer: A retrospective study from a single center". Oncology Letters 11, no. 5 (2016): 3501-3507. https://doi.org/10.3892/ol.2016.4403